Replicel Life Sciences Inc V.RP

Alternate Symbol(s): REPCF

Technology Scientific & Technical Instruments

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.

TSXV:RP - Post by User

Replicel Life Sciences Inc > Financing at market lows

<< Previous

Bullboard Posts

Next >>

Comment by Ingiboyon Mar 22, 2022 2:01pm

61 Views

Post# 34535140

RE:RE:RE:RE:RE:Financing at market lows

toniZ1 wrote: 0.18 is slap into the face of mainponte. keen to see who picked up these shares, if its primarily the mgmt we can be certain that good things are not that far away anymore. primetime for shiseido I guess....

hope for a hot summer ;-)

There is a very good chance the "Insiders" include Mainepointe. This would allow them to average down from their initial position of 4,000,000 shares at $.675.

<< Previous

Bullboard Posts

Next >>

Calibre discovers significant gold in Newfoundland